Market Closed -
Japan Exchange
07:00:00 10/05/2024 BST
|
5-day change
|
1st Jan Change
|
1,922
JPY
|
+0.47%
|
|
+2.51%
|
+17.34%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
39,017
|
47,854
|
45,709
|
81,885
|
57,557
|
54,183
|
Enterprise Value (EV)
1 |
28,073
|
34,798
|
26,900
|
58,384
|
41,002
|
35,545
|
P/E ratio
|
30.4
x
|
27.6
x
|
16.1
x
|
16.7
x
|
20.5
x
|
17.8
x
|
Yield
|
1.08%
|
0.88%
|
1.2%
|
0.65%
|
0.92%
|
1.22%
|
Capitalization / Revenue
|
0.88
x
|
1.09
x
|
1.15
x
|
2.18
x
|
1.68
x
|
1.36
x
|
EV / Revenue
|
0.63
x
|
0.79
x
|
0.68
x
|
1.55
x
|
1.2
x
|
0.89
x
|
EV / EBITDA
|
5.86
x
|
6.14
x
|
4.11
x
|
9.64
x
|
10.1
x
|
5.5
x
|
EV / FCF
|
8.71
x
|
12.9
x
|
3.84
x
|
20.1
x
|
-22.8
x
|
21.9
x
|
FCF Yield
|
11.5%
|
7.77%
|
26.1%
|
4.97%
|
-4.39%
|
4.57%
|
Price to Book
|
0.71
x
|
0.8
x
|
0.79
x
|
1.31
x
|
0.82
x
|
0.72
x
|
Nbr of stocks (in thousands)
|
35,056
|
35,058
|
34,367
|
33,219
|
33,155
|
33,079
|
Reference price
2 |
1,113
|
1,365
|
1,330
|
2,465
|
1,736
|
1,638
|
Announcement Date
|
28/03/19
|
27/03/20
|
30/03/21
|
30/03/22
|
30/03/23
|
28/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
44,308
|
44,043
|
39,639
|
37,627
|
34,274
|
39,972
|
EBITDA
1 |
4,788
|
5,667
|
6,552
|
6,056
|
4,049
|
6,463
|
EBIT
1 |
1,532
|
2,569
|
3,597
|
2,798
|
1,371
|
3,804
|
Operating Margin
|
3.46%
|
5.83%
|
9.07%
|
7.44%
|
4%
|
9.52%
|
Earnings before Tax (EBT)
1 |
2,091
|
3,066
|
4,468
|
7,489
|
3,781
|
4,562
|
Net income
1 |
1,283
|
1,732
|
2,871
|
4,953
|
2,817
|
3,045
|
Net margin
|
2.9%
|
3.93%
|
7.24%
|
13.16%
|
8.22%
|
7.62%
|
EPS
2 |
36.55
|
49.40
|
82.70
|
147.5
|
84.88
|
91.89
|
Free Cash Flow
1 |
3,221
|
2,702
|
7,010
|
2,899
|
-1,799
|
1,624
|
FCF margin
|
7.27%
|
6.14%
|
17.68%
|
7.7%
|
-5.25%
|
4.06%
|
FCF Conversion (EBITDA)
|
67.28%
|
47.69%
|
106.99%
|
47.87%
|
-
|
25.13%
|
FCF Conversion (Net income)
|
251.07%
|
156.03%
|
244.16%
|
58.53%
|
-
|
53.33%
|
Dividend per Share
2 |
12.00
|
12.00
|
16.00
|
16.00
|
16.00
|
20.00
|
Announcement Date
|
28/03/19
|
27/03/20
|
30/03/21
|
30/03/22
|
30/03/23
|
28/03/24
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2021 S1
|
2021 Q3
|
2022 Q1
|
2022 S1
|
2022 Q3
|
2023 Q1
|
2023 S1
|
2023 Q3
|
---|
Net sales
1 |
19,838
|
22,697
|
22,014
|
6,597
|
8,545
|
17,164
|
7,697
|
10,700
|
20,616
|
9,832
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
2,651
|
3,060
|
-255
|
-903
|
14
|
541
|
1,051
|
2,104
|
1,071
|
Operating Margin
|
-
|
11.68%
|
13.9%
|
-3.87%
|
-10.57%
|
0.08%
|
7.03%
|
9.82%
|
10.21%
|
10.89%
|
Earnings before Tax (EBT)
1 |
-
|
1,794
|
7,298
|
-42
|
-676
|
1,737
|
725
|
1,259
|
2,829
|
1,178
|
Net income
1 |
-
|
1,008
|
5,073
|
101
|
266
|
1,631
|
382
|
990
|
1,982
|
728
|
Net margin
|
-
|
4.44%
|
23.04%
|
1.53%
|
3.11%
|
9.5%
|
4.96%
|
9.25%
|
9.61%
|
7.4%
|
EPS
2 |
9.690
|
28.84
|
149.9
|
3.790
|
8.030
|
49.13
|
11.54
|
29.86
|
59.79
|
21.96
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/02/20
|
13/08/20
|
12/08/21
|
08/11/21
|
12/05/22
|
09/08/22
|
10/11/22
|
11/05/23
|
09/08/23
|
09/11/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
10,944
|
13,056
|
18,809
|
23,501
|
16,555
|
18,638
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
3,221
|
2,702
|
7,010
|
2,899
|
-1,799
|
1,624
|
ROE (net income / shareholders' equity)
|
1.89%
|
2.44%
|
4.03%
|
6.07%
|
2.96%
|
3.72%
|
ROA (Net income/ Total Assets)
|
0.68%
|
1.15%
|
1.63%
|
1.27%
|
0.62%
|
1.71%
|
Assets
1 |
189,933
|
150,976
|
175,844
|
388,562
|
457,157
|
177,852
|
Book Value Per Share
2 |
1,560
|
1,710
|
1,686
|
1,884
|
2,108
|
2,264
|
Cash Flow per Share
2 |
822.0
|
794.0
|
924.0
|
1,039
|
919.0
|
901.0
|
Capex
1 |
1,527
|
2,727
|
1,114
|
925
|
817
|
1,041
|
Capex / Sales
|
3.45%
|
6.19%
|
2.81%
|
2.46%
|
2.38%
|
2.6%
|
Announcement Date
|
28/03/19
|
27/03/20
|
30/03/21
|
30/03/22
|
30/03/23
|
28/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +17.34% | 407M | | +30.38% | 684B | | +26.51% | 568B | | -4.36% | 361B | | +19.30% | 329B | | +3.73% | 284B | | +16.70% | 240B | | +8.78% | 208B | | -7.93% | 200B | | +7.68% | 166B |
Other Pharmaceuticals
|